FULC
Company Description
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 80.00M | 2.81M | 6.34M | 19.16M | 8.82M | 0 | 0 | 0 |
| Net Income | (74.88M) | (9.72M) | (97.33M) | (109.87M) | (80.85M) | (70.82M) | (82.68M) | (32.59M) | (22.96M) |
| EPS | -1.18 | -0.16 | -1.59 | -2.35 | -2.22 | -2.70 | -3.49 | -1.92 | -1.36 |
| Free Cash Flow | (60.38M) | (2.50M) | (91.47M) | (99.01M) | (80.19M) | (55.00M) | (40.34M) | (31.54M) | (21.98M) |
| FCF / Share | -0.95 | -0.04 | -1.49 | -2.20 | -2.27 | -2.17 | -1.78 | -1.86 | -1.30 |
| Operating CF | (60.06M) | (2.22M) | (90.97M) | (97.05M) | (78.48M) | (53.66M) | (39.48M) | (22.56M) | (20.07M) |
| Total Assets | 366.28M | 260.72M | 257.69M | 226.69M | 235.00M | 129.58M | 110.44M | 85.77M | 4.34M |
| Total Debt | 6.44M | 8.63M | 10.82M | 13.42M | 0 | 17,000 | 50,000 | 46,000 | 34.59M |
| Cash & Equiv | 197.53M | 58.21M | 25.56M | 35.10M | 35.41M | 57.05M | 96.71M | 72.80M | 407,000 |
| Book Value | 349.00M | 243.03M | 235.19M | 198.94M | 211.54M | 95.18M | 87.15M | 76.00M | 1.32M |
| Return on Equity | -0.21 | -0.04 | -0.41 | -0.55 | -0.38 | -0.74 | -0.95 | -0.43 | -17.37 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 80.00M | 0 | 871,000 | 759,000 |
| Net Income | (26.18M) | (18.89M) | (20.33M) | (19.59M) | (17.30M) | (17.66M) | (16.57M) | (21.70M) | 55.41M | (26.87M) | (24.76M) | (24.02M) |
| EPS | -0.34 | -0.25 | -0.31 | -0.31 | -0.28 | -0.28 | -0.31 | -0.35 | 0.89 | -0.43 | -0.40 | -0.39 |
| Free Cash Flow | (16.15M) | (18.76M) | (16.96M) | (14.28M) | (13.88M) | (15.26M) | (16.99M) | (19.09M) | 58.90M | (25.31M) | (23.23M) | (22.97M) |
| FCF / Share | -0.21 | -0.25 | -0.27 | -0.23 | -0.22 | -0.24 | -0.31 | -0.31 | 0.95 | -0.41 | -0.38 | -0.37 |
| Operating CF | (16.04M) | (18.75M) | (16.80M) | (14.19M) | (13.82M) | (15.26M) | (16.76M) | (19.07M) | 58.90M | (25.28M) | (23.16M) | (22.91M) |
| Total Assets | 323.95M | 346.77M | 366.28M | 214.86M | 228.84M | 242.65M | 260.72M | 279.01M | 294.26M | 232.59M | 257.69M | 278.88M |
| Total Debt | 5.28M | 5.87M | 6.44M | 7.01M | 7.57M | 8.11M | 8.63M | 9.14M | 9.65M | 10.14M | 10.82M | 11.49M |
| Cash & Equiv | 48.47M | 50.26M | 197.53M | 47.08M | 42.59M | 42.18M | 58.21M | 72.63M | 86.70M | 39.95M | 25.56M | 30.08M |
| Book Value | 310.70M | 333.30M | 349.00M | 198.37M | 214.38M | 228.49M | 243.03M | 257.29M | 273.79M | 213.59M | 235.19M | 255.46M |
| Return on Equity | -0.08 | -0.06 | -0.06 | -0.10 | -0.08 | -0.08 | -0.07 | -0.08 | 0.20 | -0.13 | -0.11 | -0.09 |
